Recent studies have shown that the NLRP3 inflammasome regulates the development of SIRS and compensatory anti-inflammatory response syndromes (CARS) in AP mice, and inhibition of NLRP3 activation may be a useful treatment for AP patients 34-36. This evidence concerns the gene NLRP3 and alkaline phosphatase measurement.